GB1390772A - Oral narcotic composition - Google Patents
Oral narcotic compositionInfo
- Publication number
- GB1390772A GB1390772A GB1131972A GB1131972A GB1390772A GB 1390772 A GB1390772 A GB 1390772A GB 1131972 A GB1131972 A GB 1131972A GB 1131972 A GB1131972 A GB 1131972A GB 1390772 A GB1390772 A GB 1390772A
- Authority
- GB
- United Kingdom
- Prior art keywords
- narcotic
- salts
- composition
- orally
- injection
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
Landscapes
- Health & Medical Sciences (AREA)
- Emergency Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
1390772 Narcotic compositions ENDO LABORATORIES INC 10 March 1972 [7 May 1971] 11319/72 Heading A5B Pharmaceutical compositions comprise: (a) a compound, having substantial narcotic activity both orally and by injection, selected from oxycodone, hydrocodone, codeine, propoxyphene and pentazocine, and salts thereof and, (b) a narcotic antagonist which is substantially less active orally than by injection selected from: (i) naloxone and its pharmaceutically acceptable salts, (ii) N-cyclopropylmethyl-7, 8-dihydro-14-hydroxynormophinone and its salts and, (iii) 21-cyclopropyl-7#-(1- hydroxy-1-methylethyl)-6, 14-endo-ethano-tetrahydrooripavine and its salts, the weight ratio of (a) to (b) being within certain ranges according to the individual compounds used so that substance (b) does not block the narcotic effect of (a) when the composition is administered orally, but does prevent an acute euphoriant effect by (a) when the composition is injected. Other active substances may also be present, e.g. aspirin, phenacetin, caffeine, antihistamines and antispasmodics.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US14140771A | 1971-05-07 | 1971-05-07 |
Publications (1)
Publication Number | Publication Date |
---|---|
GB1390772A true GB1390772A (en) | 1975-04-16 |
Family
ID=22495561
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
GB1131972A Expired GB1390772A (en) | 1971-05-07 | 1972-03-10 | Oral narcotic composition |
Country Status (3)
Country | Link |
---|---|
DE (1) | DE2222039A1 (en) |
FR (1) | FR2137560B1 (en) |
GB (1) | GB1390772A (en) |
Cited By (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0900582A1 (en) * | 1997-08-21 | 1999-03-10 | Johnson Matthey Public Limited Company | Method for removal of residual organic solvents from a crystalline bulk substance and use thereof in manufacturing pharmaceuticals |
WO2003007802A2 (en) * | 2001-07-18 | 2003-01-30 | Euro-Celtique, S.A. | Pharmaceutical combinations of oxycodone and naloxone |
EP1299104A1 (en) * | 2000-02-08 | 2003-04-09 | Euro-Celtique, S.A. | Tamper-resistant oral opioid agonist formulations |
WO2003084520A2 (en) * | 2002-04-05 | 2003-10-16 | Euro-Celtique S.A. | Pharmaceutical preparation containing oxycodone and naloxone |
EP1810678A1 (en) * | 2006-01-19 | 2007-07-25 | Holger Lars Hermann | Use of morphine and naloxone for drug substitution |
US8465774B2 (en) | 2001-08-06 | 2013-06-18 | Purdue Pharma L.P. | Sequestered antagonist formulations |
US8518925B2 (en) | 2004-06-08 | 2013-08-27 | Euro-Celtique S.A. | Opioids for the treatment of the chronic obstructive pulmonary disease (COPD) |
US8673355B2 (en) | 1997-12-22 | 2014-03-18 | Purdue Pharma L.P. | Opioid agonist/antagonist combinations |
US8822487B2 (en) | 1997-12-22 | 2014-09-02 | Purdue Pharma L.P. | Opioid agonist/opioid antagonist/acetaminophen combinations |
US8969369B2 (en) | 2001-05-11 | 2015-03-03 | Purdue Pharma L.P. | Abuse-resistant controlled-release opioid dosage form |
US9101625B2 (en) | 2006-08-30 | 2015-08-11 | Purdue Pharma L.P. | Buprenorphine-wafer for drug substitution therapy |
US9271940B2 (en) | 2009-03-10 | 2016-03-01 | Purdue Pharma L.P. | Immediate release pharmaceutical compositions comprising oxycodone and naloxone |
US10071089B2 (en) | 2013-07-23 | 2018-09-11 | Euro-Celtique S.A. | Combination of oxycodone and naloxone for use in treating pain in patients suffering from pain and a disease resulting in intestinal dysbiosis and/or increasing the risk for intestinal bacterial translocation |
US10258235B2 (en) | 2005-02-28 | 2019-04-16 | Purdue Pharma L.P. | Method and device for the assessment of bowel function |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4366159A (en) * | 1981-09-08 | 1982-12-28 | Michael Richard Magruder | Nalbuphine-narcotic analgesic composition and method of producing analgesia |
GB8332556D0 (en) * | 1983-12-06 | 1984-01-11 | Reckitt & Colmann Prod Ltd | Analgesic compositions |
WO1993002707A1 (en) * | 1991-08-06 | 1993-02-18 | Byk Gulden Lomberg Chemische Fabrik Gmbh | New anti-diarrheic agents |
FR2681922B1 (en) * | 1991-09-30 | 1993-11-26 | Bendix Europe Services Technique | FRICTION MEMBER PROVIDED WITH A WEAR INDICATOR DEVICE AND DISC BRAKE EQUIPPED WITH SUCH A MEMBER. |
RU2228180C2 (en) | 1997-12-22 | 2004-05-10 | Эро-Селтик, С.А. | Method for prevention abuse with opioid- -containing medicinal formulations |
US6716449B2 (en) | 2000-02-08 | 2004-04-06 | Euro-Celtique S.A. | Controlled-release compositions containing opioid agonist and antagonist |
IL160222A0 (en) | 2001-08-06 | 2004-07-25 | Euro Celtique Sa | Opioid agonist formulations with releasable and sequestered antagonist |
US7815934B2 (en) | 2002-09-20 | 2010-10-19 | Alpharma Pharmaceuticals, Llc | Sequestering subunit and related compositions and methods |
TWI347201B (en) | 2003-04-21 | 2011-08-21 | Euro Celtique Sa | Pharmaceutical products,uses thereof and methods for preparing the same |
PT2719378T (en) | 2006-06-19 | 2016-11-02 | Alpharma Pharmaceuticals Llc | Pharmaceutical compositions |
US8623418B2 (en) | 2007-12-17 | 2014-01-07 | Alpharma Pharmaceuticals Llc | Pharmaceutical composition |
-
1972
- 1972-03-10 GB GB1131972A patent/GB1390772A/en not_active Expired
- 1972-05-05 FR FR7216146A patent/FR2137560B1/fr not_active Expired
- 1972-05-05 DE DE19722222039 patent/DE2222039A1/en active Pending
Cited By (57)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5981751A (en) * | 1997-08-12 | 1999-11-09 | Johnson Matthey Public Limited Company | Method for removal of residual organic solvents and use thereof in manufacturing pharmaceuticals |
EP0900582A1 (en) * | 1997-08-21 | 1999-03-10 | Johnson Matthey Public Limited Company | Method for removal of residual organic solvents from a crystalline bulk substance and use thereof in manufacturing pharmaceuticals |
US9205082B2 (en) | 1997-12-22 | 2015-12-08 | Purdue Pharma L.P. | Opioid agonist/antagonist combinations |
US8932630B1 (en) | 1997-12-22 | 2015-01-13 | Purdue Pharma L.P | Opioid agonist/antagonist combinations |
US8822487B2 (en) | 1997-12-22 | 2014-09-02 | Purdue Pharma L.P. | Opioid agonist/opioid antagonist/acetaminophen combinations |
US8673355B2 (en) | 1997-12-22 | 2014-03-18 | Purdue Pharma L.P. | Opioid agonist/antagonist combinations |
US8586088B2 (en) | 2000-02-08 | 2013-11-19 | Purdue Pharma L.P. | Tamper-resistant oral opioid agonist formulations |
US7682632B2 (en) | 2000-02-08 | 2010-03-23 | Purdue Pharma L.P. | Tamper-resistant oral opioid agonist formulations |
US10588865B2 (en) | 2000-02-08 | 2020-03-17 | Purdue Pharma L.P. | Tamper resistant oral opioid agonist formulations |
AP1665A (en) * | 2000-02-08 | 2006-09-22 | Euro Celtique Sa | Tamper-resistant oral opioid agonist formulations. |
US10350173B2 (en) | 2000-02-08 | 2019-07-16 | Purdue Pharma L.P. | Tamper resistant oral opioid agonist formulations |
US9801828B2 (en) | 2000-02-08 | 2017-10-31 | Purdue Pharma L.P. | Tamper resistant oral opioid agonist formulations |
US9456989B2 (en) | 2000-02-08 | 2016-10-04 | Purdue Pharma L.P. | Tamper-resistant oral opioid agonist formulations |
CZ299991B6 (en) * | 2000-02-08 | 2009-01-14 | Euro-Celtique S.A. | Medicamentous dosage form |
US7658939B2 (en) | 2000-02-08 | 2010-02-09 | Purdue Pharma L.P. | Tamper-resistant oral opioid agonist formulations |
US8357399B2 (en) | 2000-02-08 | 2013-01-22 | Purdue Pharma L.P. | Tamper-resistant oral opioid agonist formulations |
US7718192B2 (en) * | 2000-02-08 | 2010-05-18 | Purdue Pharma L.P. | Tamper-resistant oral opioid agonist formulations |
US9278073B2 (en) | 2000-02-08 | 2016-03-08 | Purdue Pharma L.P. | Tamper-resistant oral opioid agonist formulations |
US7842311B2 (en) | 2000-02-08 | 2010-11-30 | Purdue Pharma L.P. | Tamper-resistant oral opioid agonist formulations |
US7842309B2 (en) | 2000-02-08 | 2010-11-30 | Purdue Pharma L.P. | Tamper-resistant oral opioid agonist formulations |
EP1299104A4 (en) * | 2000-02-08 | 2004-04-21 | Euro Celtique Sa | Tamper-resistant oral opioid agonist formulations |
US8936812B2 (en) | 2000-02-08 | 2015-01-20 | Purdue Pharma L.P. | Tamper-resistant oral opioid agonist formulations |
US8236351B2 (en) | 2000-02-08 | 2012-08-07 | Purdue Pharma L.P. | Tamper-resistant oral opioid agonist formulations |
EP1299104A1 (en) * | 2000-02-08 | 2003-04-09 | Euro-Celtique, S.A. | Tamper-resistant oral opioid agonist formulations |
US8969369B2 (en) | 2001-05-11 | 2015-03-03 | Purdue Pharma L.P. | Abuse-resistant controlled-release opioid dosage form |
AU2002316738B2 (en) * | 2001-07-18 | 2009-01-08 | Euro-Celtique S.A. | Pharmaceutical combinations of oxycodone and naloxone |
WO2003007802A2 (en) * | 2001-07-18 | 2003-01-30 | Euro-Celtique, S.A. | Pharmaceutical combinations of oxycodone and naloxone |
WO2003007802A3 (en) * | 2001-07-18 | 2003-11-27 | Euro Celtique Sa | Pharmaceutical combinations of oxycodone and naloxone |
US8465774B2 (en) | 2001-08-06 | 2013-06-18 | Purdue Pharma L.P. | Sequestered antagonist formulations |
US8758825B2 (en) | 2001-08-06 | 2014-06-24 | Purdue Pharma L.P. | Sequestered antagonist formulations |
JP2010180233A (en) * | 2002-04-05 | 2010-08-19 | Euro-Celtique Sa | Pharmaceutical preparation containing oxycodone and naloxone |
EP2425825B1 (en) | 2002-04-05 | 2016-11-16 | Euro-Celtique S.A. | Pharmaceutical preparation containing oxycodone and naloxone |
US10420762B2 (en) | 2002-04-05 | 2019-09-24 | Purdue Pharma L.P. | Pharmaceutical preparation containing oxycodone and naloxone |
CN1646102B (en) * | 2002-04-05 | 2012-08-15 | 欧洲凯尔蒂克公司 | Pharmaceutical preparation containing oxycodone and naloxone |
JP4755810B2 (en) * | 2002-04-05 | 2011-08-24 | ユーロ−セルティーク エス.エイ. | Pharmaceutical formulation containing oxycodone and naloxone |
US9655855B2 (en) | 2002-04-05 | 2017-05-23 | Purdue Pharma L.P. | Matrix for sustained, invariant and independent release of active compounds |
EP1492505B1 (en) | 2002-04-05 | 2015-06-03 | Euro-Celtique S.A. | Pharmaceutical preparation containing oxycodone and naloxone |
WO2003084520A2 (en) * | 2002-04-05 | 2003-10-16 | Euro-Celtique S.A. | Pharmaceutical preparation containing oxycodone and naloxone |
WO2003084520A3 (en) * | 2002-04-05 | 2004-03-11 | Euro Celtique Sa | Pharmaceutical preparation containing oxycodone and naloxone |
AU2003224040B2 (en) * | 2002-04-05 | 2006-06-22 | Mundipharma Pty Limited | Pharmaceutical preparation containing oxycodone and naloxone |
US9555000B2 (en) | 2002-04-05 | 2017-01-31 | Purdue Pharma L.P. | Pharmaceutical preparation containing oxycodone and naloxone |
US8846091B2 (en) | 2002-04-05 | 2014-09-30 | Euro-Celtique S.A. | Matrix for sustained, invariant and independent release of active compounds |
US8846090B2 (en) | 2002-04-05 | 2014-09-30 | Euro-Celtique S.A. | Matrix for sustained, invariant and independent release of active compounds |
US9907793B2 (en) | 2002-04-05 | 2018-03-06 | Purdue Pharma L.P. | Pharmaceutical preparation containing oxycodone and naloxone |
US8518925B2 (en) | 2004-06-08 | 2013-08-27 | Euro-Celtique S.A. | Opioids for the treatment of the chronic obstructive pulmonary disease (COPD) |
US10258235B2 (en) | 2005-02-28 | 2019-04-16 | Purdue Pharma L.P. | Method and device for the assessment of bowel function |
EA014539B1 (en) * | 2006-01-19 | 2010-12-30 | Фенукс Аг | Use of a combination of morphine and at least one opiate antagonists for treatment of opiate dependency and for prevention of non-oral opiate abuse in opiate addicts |
US10507205B2 (en) | 2006-01-19 | 2019-12-17 | Purdue Pharmaceutical Products L.P. | Methods of treating opiate dependency and preventing non-oral opiate abuse among opiate addicts |
WO2007082935A1 (en) * | 2006-01-19 | 2007-07-26 | Phoenux Ag | Use of a combination of morphine and at least one opiate antagonist for treatment of opiate dependency and for prevention of non-oral opiate abuse in opiate addicts |
EP1810678A1 (en) * | 2006-01-19 | 2007-07-25 | Holger Lars Hermann | Use of morphine and naloxone for drug substitution |
US9101625B2 (en) | 2006-08-30 | 2015-08-11 | Purdue Pharma L.P. | Buprenorphine-wafer for drug substitution therapy |
US9861628B2 (en) | 2006-08-30 | 2018-01-09 | Rhodes Pharmaceuticals L.P. | Buprenorphine-wafer for drug substitution therapy |
US9763931B2 (en) | 2006-08-30 | 2017-09-19 | Purdue Pharma L.P. | Buprenorphine-wafer for drug substitution therapy |
US9370512B2 (en) | 2006-08-30 | 2016-06-21 | Purdue Pharma L.P. | Buprenorphine-wafer for drug substitution therapy |
US9820983B2 (en) | 2009-03-10 | 2017-11-21 | Purdue Pharma L.P. | Immediate release pharmaceutical compositions comprising oxycodone and naloxone |
US9271940B2 (en) | 2009-03-10 | 2016-03-01 | Purdue Pharma L.P. | Immediate release pharmaceutical compositions comprising oxycodone and naloxone |
US10071089B2 (en) | 2013-07-23 | 2018-09-11 | Euro-Celtique S.A. | Combination of oxycodone and naloxone for use in treating pain in patients suffering from pain and a disease resulting in intestinal dysbiosis and/or increasing the risk for intestinal bacterial translocation |
Also Published As
Publication number | Publication date |
---|---|
FR2137560A1 (en) | 1972-12-29 |
FR2137560B1 (en) | 1975-10-31 |
DE2222039A1 (en) | 1972-11-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
GB1390772A (en) | Oral narcotic composition | |
GB1517480A (en) | Opiate analgesic formulation with a low potential for abuse | |
FI905718A (en) | TRANSDERMALT MEDEL. | |
NZ177159A (en) | Clavulanic acid, salts, esters and preparation thereof from streptomyces clavuligerus: pharmaceutical compositions | |
ES460098A1 (en) | Derivatives of penicillanic acid | |
GB841697A (en) | Analgesic compositions | |
GB1321509A (en) | Azepine derivatives | |
IE782422L (en) | Dispersions of clavulanic acid particles | |
GB1487334A (en) | Pharmaceutical preparations comprising lisuride and/or physiologically tolerable salts thereof | |
GB1183403A (en) | Antitussive Medicament with Prolonged Effect | |
WO1991018606A3 (en) | Orally active nonaddicting analgesics | |
GB1174051A (en) | Aminophenol Derivatives and Analgesic and Antipyretic Compositions | |
GB1463505A (en) | Pharmaceutical compositions | |
GB1442159A (en) | Pharmaceutical compositions containing paracetamol | |
GB1349138A (en) | Quinazoline derivative | |
ES8306593A1 (en) | Compositions for topical use containing Ergot or Vinca Rosea alkaloids for treatment of hyperseborrhoea, and their preparation. | |
GB1507643A (en) | 4-(5-nitro-2-furyl)quinaldinic acid n-oxide and its use in the treatment of bovine mastitis | |
US3800041A (en) | Analgesic compositions and methods | |
US3795736A (en) | 5,5-dimethyl-10-hydroxy-8-(3-methyl-2-octyl)-2-(2-propynyl)-1,2,3,4-tetrahydro-5h-(1) benzopyrano(3,4-d)pyridine as an analgesic agent | |
GB1302353A (en) | ||
GB1254057A (en) | Improvements in or relating to therapeutical composition containing vincamine | |
RU2083202C1 (en) | Analgetic preparation | |
GB1261454A (en) | Improved analgesic systems and compositions | |
IL38864A (en) | Pharmaceutical compositions containing a pharmaceutically active penicillin and a penicilloic acid derivative | |
GB1395772A (en) | 1-aryl-3h-1,4-benzodiazepin-2,5-1h,4h-diones |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PS | Patent sealed | ||
PLNP | Patent lapsed through nonpayment of renewal fees | ||
49R | Reference inserted (sect. 9/1949) | ||
SP | Amendment (slips) printed |